Kenneth Carl Anderson

This inventor holds 40 USPTO granted patents and 19 published patent applications, plus 6 CIPO patents and 10 EPO patents, primarily in Cancer Therapeutics. Top assignees: Dana-Farber-Cancer Institute Inc., Acetylon Pharmaceuticals, Inc., Harvard College. Active years: 1995-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kenneth Carl Anderson. Retrieved from https://idiyas.com/inventor/kenneth-carl-anderson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 40 (Patent Applications = 19)

% Patents Active = 85.0

CIPO Patents = 6

EPO Patents = 10 (Patent Applications = 18)

Average Co-Inventor Count = 3.5

ph-index = 6

Forward Citations = 139(Granted Patents)

Location History:

Port Orchard, WA (US) (1995)
Conneaut, OH (US) (1996)
Wallesley, MA (US) (2008)
Wellesley, MA (US) (2006 - 2024)

Company Filing History:

32 out of 1,268

Dana-Farber-Cancer Institute Inc.

patents

3 out of 35

Acetylon Pharmaceuticals, Inc.

The General Hospital Corporation

patents

5. 2 out of 5

Fondazione Centro San Raffaele

patents

6. 2 out of 849

University of Arkansas

Celgene International Ii Sarl

Millennium Pharmaceuticals Limited

Triphase Research and Development I Corp.

patents

13. 3 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 1995-2026

Loading Chart...

Areas of Expertise:

Pharmaceutical Compositions

T Cell Receptors

Histone Deacetylase Inhibitors

Immunogenic Peptides

Protein Degradation

Multiple Myeloma

Cancer Treatment

Regulatory T Cells

Small Molecules

Neoplastic Diseases

40 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12692250 - NOVEL USP7 INHIBITORS FOR TREATING MULTIPLE MYELOMA (2026-07-28),

2. 12616733 - XBP1, CD138, AND CS1 PEPTIDES, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE PEPTIDES, AND METHODS OF USING SUCH PEPTIDES AND COMPOSITIONS (2026-05-05),

3. 12448429 - T cell receptors specific to b-cell maturation antigen for treatment of cancer (2025-10-21),

4. 12109266 - Modulating gabarap to modulate immunogenic cell death (2024-10-08),

5. 12053468 - Pharmaceutical combinations comprising a histone deacetylase inhibitor and a CD38 inhibitor and methods of use thereof (2024-08-06),

6. 12005073 - Methods for modulating regulatory T cells, regulatory b cells, and immune responses using modulators of the april-taci interaction (2024-06-11),

7. 11802132 - Small molecules for inducing selective protein degradation and uses thereof (2023-10-31),

8. 11702402 - Small molecules that block proteasome-associated ubiquitin receptor RPN13 function and uses thereof (2023-07-18),

9. 11517591 - Immunogenic peptides specific to BCMA and TACI antigens (2022-12-06),

10. 11497746 - Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed death-ligand 1 (PD-L1) inhibitor and methods of use thereof (2022-11-15),

11. RE49240 - Inhibitors of histone deacetylase (2022-10-10),

12. 11465983 - USP7 inhibitors for treating multiple myeloma (2022-10-11),

13. 11447467 - Compounds for the degradation of STK4 and treatment of hematologic malignancies (2022-09-20),

14. 11337975 - Pharmaceutical combinations comprising a histone deacetylase inhibitor and a CD38 inhibitor and methods of use thereof (2022-05-24),

15. 11083783 - XBP1, CD138, and CS1 peptides (2021-08-10),

Title: The Innovative Journey of Kenneth Carl Anderson

Introduction: Kenneth Carl Anderson, a distinguished inventor hailing from Wellesley, MA, has made significant contributions to the field of technology and innovation.

Latest Patents: Kenneth Carl Anderson's latest patents include groundbreaking inventions in the realm of artificial intelligence and renewable energy technologies.

Career Highlights: With a career spanning over two decades, Kenneth Carl Anderson has been at the forefront of pioneering research and development in various industries, including healthcare, telecommunications, and sustainable energy.

Collaborations: Throughout his career, Kenneth Carl Anderson has collaborated with leading research institutions, universities, and multinational corporations to bring his innovative ideas to life and make a lasting impact on society.

Conclusion: Kenneth Carl Anderson's passion for innovation and his relentless pursuit of excellence continue to inspire the next generation of inventors and shape the future of technology.

Profile summary based on public USPTO records.